Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Slides
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP21: Potential mechanisms linking biological therapies on SARS-CoV-2 susceptibility in Inflammatory Bowel Disease patientsECCO'22
Year: 2022
Authors: Pisani, L.F.(1);Mola, S.(2,3);Crespi, G.(2,3);Caprioli, F.(4,5);Pastorelli, L.(6,7);Annunziata, M.L.(1);Manfredi, M.(3,8);Porta, C.(2,3);
(1)IRCCS Policlinico San Donato, Gastroenterology and Endoscopy Unit, San Donato Milanese, Italy;(2)University of Piemonte Orientale, Department of Pharmaceutical Sciences, Novara, Italy;(3)University of Piemonte Orientale, Center for Translational Research on Autoimmune and Allergic Diseases, Novara, Italy;(4)University of Milan, Department of Medical-Surgical Physiopathology and Transplantation, Milan, Italy;(5)Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Gastroenterology and Endoscopy Unit, Milan, Italy;(6)University of Milan, Department of Health Sciences, Milan, Italy;(7)ASST Santi Paolo e Carlo, Gastroenterology and Liver Unit, Milan, Italy;(8)University of Piemonte Orientale, Department of Translational Medicine, Novara, Italy;
DOP22: Clinical, biochemical and endoscopic disease activity of Inflammatory Bowel Diseases are not associated with the severity or long-term outcomes of COVID-19 – A Danish prospective population-based cohort studyECCO'22
Year: 2022
Authors: Attauabi, M.(1,2,3);Dahlerup, J.F.(4);Poulsen, A.(5);Hansen, M.R.(6);Vester-Andersen, M.K.(7);Eraslan, S.(2);Prahm, A.P.(5);Pedersen, N.(8);Larsen, L.(9);Jess, T.(9,10);Neumann, A.(11);Haderslev, K.V.(12);Molazahi, A.(13);Lødrup, A.B.(14);Glerup, H.(15);Oppfeldt, A.M.(16);Jensen, M.D.(17);Theede, K.(1,3);Kiszka-Kanowitz, M.(1,3);Seidelin, J.B.(2);Burisch, J.(1,3); Danish COVID-IBD Study Group
(1)Copenhagen University Hospital- Hvidovre, Gastrounit- Medical Section, Hvidovre, Denmark;(2)Herlev Hospital- University of Copenhagen, Department of Gastroenterology and Hepatology, Herlev, Denmark;(3)University of Copenhagen- Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(4)Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark;(5)Bispebjerg University Hospital, Digestive Disease Center, Copenhagen, Denmark;(6)North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark;(7)Zealand University Hospital- Koege, Department of Internal Medicine, Koege, Denmark;(8)Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark;(9)Aalborg University Hospital, Department of Gastroenterology and Hepatology, Aalborg, Denmark;(10)Aalborg University, National Center of Excellence for Molecular Prediction of Inflammatory Bowel Disease PREDICT- Department of Clinical Medicine, Copenhagen, Denmark;(11)Region Hospital Viborg, Department of Internal Medicine, Viborg, Denmark;(12)Rigshospitalet- Copenhagen University Hospital, Department of Gastroenterology, Copenhagen, Denmark;(13)Holbaek Hospital, Department of Internal Medicine, Holbaek, Denmark;(14)Region Hospital West Jutland- Herning, Department of Internal Medicine, Herning, Denmark;(15)Region Hospital Silkeborg, Department of Internal Medicine, Silkeborg, Denmark;(16)Region Hospital Horsens, Department of Internal Medicine, Horsens, Denmark;(17)Lillebaelt Hospital- Vejle, Department of Internal Medicine- Section of Gastroenterology, Vejl, Denmark;
DOP23: Long-term health consequences of COVID-19 in patients with Inflammatory Bowel Diseases – A Danish prospective population-based cohort studyECCO'22
Year: 2022
Authors: Attauabi, M.(1,2,3);Dahlerup, J.F.(4);Poulsen, A.(5);Hansen, M.R.(6);Vester-Andersen, M.K.(7);Eraslan, S.(2);Prahm, A.P.(5);Pedersen, N.(8);Larsen, L.(9);Jess, T.(9,10);Neumann, A.(11);Haderslev, K.V.(12);Molazahi, A.(13);Lødrup, A.B.(14);Glerup, H.(15);Oppfeldt, A.M.(16);Jensen, M.D.(17);Theede, K.(1,3);Kiszka-Kanowitz, M.(1,3);Seidelin, J.B.(2);Burisch, J.(1,3); Danish COVID-IBD Study Group
(1)Copenhagen University Hospital- Hvidovre, Gastrounit- Medical Section, Hvidovre, Denmark;(2)Herlev Hospital- University of Copenhagen, Department of Gastroenterology and Hepatology, Herlev, Denmark;(3)University of Copenhagen- Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(4)Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark;(5)Bispebjerg University Hospital, Digestive Disease Center, Copenhagen, Denmark;(6)North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark;(7)Zealand University Hospital- Koege, Department of Internal Medicine, Koege, Denmark;(8)Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark;(9)Aalborg University Hospital, Department of Gastroenterology and Hepatology, Aalborg, Denmark;(10)Aalborg University, National Center of Excellence for Molecular Prediction of Inflammatory Bowel Disease PREDICT- Department of Clinical Medicine, Copenhagen, Denmark;(11)Region Hospital Viborg, Department of Internal Medicine, Viborg, Denmark;(12)Rigshospitalet- Copenhagen University Hospital, Department of Gastroenterology, Copenhagen, Denmark;(13)Holbaek Hospital, Department of Internal Medicine, Holbaek, Denmark;(14)Region Hospital West Jutland- Herning, Department of Internal Medicine, Herning, Denmark;(15)Region Hospital Silkeborg, Department of Internal Medicine, Silkeborg, Denmark;(16)Region Hospital Horsens, Department of Internal Medicine, Horsens, Denmark;(17)Lillebaelt Hospital, Department of Internal Medicine- Section of Gastroenterology, Vejle, Denmark;
DOP24: Japan prospective multicenter study for optimization of COVID-19 vaccinations based on the immune response and safety profile in Inflammatory Bowel Disease patients: Interim analyses of the J-COMBAT trialECCO'22
Year: 2022
Authors: WatanabeDirector of division- Assistan, K.(1);Hisamatsu, T.(2);Nakase, H.(3);Nagase, K.(1);Matsuura, M.(2);Aoyama, N.(4);Kobayashi, T.(5);Sakuraba, H.(6);Yokoyama, K.(7);Nishishita, M.(8);Esaki , M.(9);Hirai, F.(10);Nagahori, M.(11);Nanjo, S.(12);Omori, T.(13);Tanida, S.(14);Yokoyama, Y.(3);Moriya, K.(15);Maemoto, A.(16);Handa, O.(17);Ohmiya, N.(18);Shinzaki, S.(19);Kato, S.(20);Tanaka, H.(21);Uraoka, T.(22);Takatsu, N.(23);Suzuki, H.(24);Takahashi, K.(25);Umeno, J.(26);Mishima, Y.(27);Tsuchida, K.(28);Fujiya, M.(29);Hiraoka, S.(30);Yamamoto, S.(31);Saruta, M.(32);Nojima, M.(33);Andoh, A.(25);
(1)Hyogo College of Medicine, Center for Inflammatory Bowel Disease- Division of Internal Medicine, Hyogo, Japan;(2)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(3)Sapporo Medical University School of Medicine, Gastroenterology and Hepatology, Sapporo, Japan;(4)Aoyama Medical Clinic, Gastroenterology, Kobe, Japan;(5)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(6)Hirosaki University Graduate School of Medicine, Gastroenterology and Hematology, Hirosaki, Japan;(7)Kitasato University School of Medicine, Department of Gastroenterology, Sagamihara, Japan;(8)Nishishita GI Hospital, Gastroenterology, Osaka, Japan;(9)Saga University, Division of Gastroenterology- Department of Internal Medicine, Saga, Japan;(10)Faculty of Medicine Fukuoka University, Gastroenterology, Fukuoka, Japan;(11)Tokyo Medical and Dental University Hospital, Gastroenterology and Hepatology, Tokyo, Japan;(12)University of Toyama, Third Department of Internal Medicine- Graduate School of Medicine, Toyama, Japan;(13)Tokyo Women’s Medical University, Institute of Gastroenterology, Tokyo, Japan;(14)Nagoya City University, Gastroenterology and Metabolism, Nagoya, Japan;(15)Nara Medical University, Department of Gastroenterology and Hepatology, Kashihara, Japan;(16)Sapporo Higashi Tokushukai Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan;(17)Kawasaki Medical School, Internal Medicine- Division of Gastroenterology, Kurashiki, Japan;(18)Fujita Health University, Department of Advanced Endoscopy, Toyoake, Japan;(19)Osaka University Graduate School of Medicine, Gastroenterology and Hepatology, Suita, Japan;(20)Saitama Medical Center- Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan;(21)Sapporo IBD Clinic, Inflammatory Bowel Disease, Sapporo, Japan;(22)Gunma University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Maebashi, Japan;(23)Fukuoka University Chikushi Hospital, Inflammatory bowel disease center, Chikushino, Japan;(24)Faculty of Medicine- University of Tsukuba, Gastroenterology, Tsukuba, Japan;(25)Shiga University of Medical Science, Gastroenterology, Otsu, Japan;(26)Kyushu University, Medicine and Clinical Science- Graduate School of Medical Sciences Graduate School of Medical Sciences, Fukuoka, Japan;(27)Shimane University Faculty of Medicine, Department of Internal Medicine II, Izumo, Japan;(28)Nagoya City University West Medical Center, Gastroenterology, Nagoya, Japan;(29)Asahikawa Medical University, Department of Medicine, Asahikawa, Japan;(30)Okayama University Graduate School of Medicine- Dentistry and Pharmaceutical Sciences, Gastroenterology and Hepatology, Okayama, Japan;(31)Graduate School of Medicine- Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan;(32)The Jikei University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Tokyo, Japan;(33)The University of Tokyo, The Institute of Medical Science, Tokyo, Japan;J-COMBAT trial group
DOP25: Clinical outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel DiseaseECCO'22
Year: 2022
Authors: Wetwittayakhlang, P.(1);Albader, F.(2);Golovics, P.(1);Drügg Hahn, G.(1);Bessissow, T.(1); Bitton, A.(1); Afif, W.(1);Wild, G.(1);LakatosPhD, P.L.(1); Inflammatory bowel disease McGill University Health Centre
(1)Mcgill University Health Center, IBD Centre, Montréal, Canada;(2)Mcgill University Health Center, Division of Internal Medicine, Montréal, Canada;
DOP26: COVID-19 vaccine effectiveness in Inflammatory Bowel Disease patients on tumor-necrosis factor inhibitors: Real world data from a mass-vaccination campaignECCO'22
Year: 2022
Authors: Lev Zion, R.(1);Focht, G.(1);Lujan, R.(1);Mendelovici, A.(1);Friss, C.(1);Greenfeld, S.(2);Kariv, R.(3);Ben-Tov, A.(4,5);Matz, E.(6);Nevo, D.(7);Barak-Corren, Y.(8);Dotan, I.(9);Turner, D.(10);
(1)Shaare Zedek Medical Center, Department of Pediatric Gastroenterology, Jerusalem, Israel;(2)Maccabi Health Services and the Sackler Faculty of Medicine- Tel Aviv University, Medical Informatics, Tel-Aviv, Israel;(3)Maccabi Health Services and the Sackler Faculty of Medicine- Tel Aviv University, Gastroenterology, Tel-Aviv, Israel;(4)Maccabi Health Services and the Sackler Faculty of Medicine- Tel Aviv University, Institute for Research & Innovation, Tel-Aviv, Israel;(5)Dana-Dwek Children's Hospital- Tel-Aviv Sourasky Medical Center, Pediatric Gastroenterology, Tel-Aviv, Israel;(6)Leumit Health Services, Community Medicine, Tel-Aviv, Israel;(7)Tel-Aviv University, Department of Statistics and Operations Research, Tel-Aviv, Israel;(8)Boston Children's Hospital, Predictive Medicine Group, Boston, United States;(9)Rabin Medical Center and the Sackler Faculty of Medicine- Tel Aviv University, Gastroenterology, Petah Tikva, Israel;(10)Shaare Zedek Medical Center and the Hebrew University of Jerusalem, Department of Pediatric Gastroenterology, Jerusalem, Israel;
DOP27: Humoral immune response after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases treated with immunosuppressive therapy - a Target to B! studyECCO'22
Year: 2022
Authors: Volkers , A.(1);Wieske , L.(2);van Dam , K.(2);Steenhuis , M.(3);Stalman , E.(2);Kummer , L.(2);van Kempen , Z.(4);Killestein , J.(4);Tas , S.(5);Boekel , L.(6);Wolbink , G.(6);Takkenberg , B.(1);Spuls , P.(7);Bosma , A.(7);Rutgers , B.(8);Verschuuren , J.(9);van Ouwerkerk , L.(10);van der Woude , D.(10);van Paassen , P.(11);Busch , M.(11);Brusse , E.(12);Hijnen , D.(13);ten Brinke , A.(3);Verstegen , N.(3);D'Haens , G.(1);van Ham , M.(3);Kuijpers , T.(14);Rispens , T.(3);Löwenberg , M.(1);Eftimov , F.(2); on behalf of the T2B! immunity against SARS-CoV-2 study group
(1)Amsterdam UMC- location AMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC- location AMC, Department of Neurology and Neurophysiology, Amsterdam, The Netherlands;(3)Sanquin, Department of immunopathology, Amsterdam, The Netherlands;(4)Amsterdam UMC- location VU University medical center, Department of Neurology, Amsterdam, The Netherlands;(5)Amsterdam UMC, Department of Rheumatology and Clinical Immunology, Amsterdam, The Netherlands;(6)Amsterdam Rheumatology and immunology Center- location Reade, Department of Rheumatology, Amsterdam, The Netherlands;(7)Amsterdam UMC- location Academic Medical Center, Department of Dermatology, Amsterdam, The Netherlands;(8)University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, The Netherlands;(9)Leiden University Medical Center, Department of Neurology, Leiden, The Netherlands;(10)Leiden University Medical Center, Department of Rheumatology, Leiden, The Netherlands;(11)Maastricht University Medical Center, Department of Nephrology and Clinical Immunology, Maastricht, The Netherlands;(12)Erasmus MC University Medical Center, Department of Neurology, Rotterdam, The Netherlands;(13)Erasmus MC University Medical Center, Department of Dermatology, Rotterdam, The Netherlands;(14)Amsterdam UMC- location AMC, Department of Pediatric Immunology- Rheumatology and Infectious Disease, Amsterdam, The Netherlands;
DOP28: Venous thromboembolism following discharge from hospital in patients admitted for Inflammatory Bowel DiseaseECCO'22
Year: 2022
Authors: Harvey, P.(1);Coupland, B.(2);Mytton, J.(2);Trudgill, N.(3);De Silva, S.(4);
(1)The Royal Wolverhampton NHS trust, Department of Gastroenterology, Wolverhampton, United Kingdom;(2)University Hospital Birmingham, Healthcare Informatics, Birmingham, United Kingdom;(3)Sandwell and West Birmingham NHS Trust, Gastroenterology, Birmingham, United Kingdom;(4)Dudley Group NHS Trust, Gastroenterology, Birmingham, United Kingdom;
DOP29: A novel predictive scoring system of venous thromboembolism after surgery for Inflammatory Bowel Disease: A NSQIP-IBD registry analysisECCO'22
Year: 2022
Authors: Cheong, J.Y.(1);Connelly, T.(1);Prien, C.(1);Jia, X.(1);Valente, M.(1);Bhama, A.(1);Lightner, A.(1);HolubarMD- MS, S.(1);
(1)Cleveland Clinic, Department of Colon & Rectal Surgery, Cleveland, United States;
DOP30: Long-term outcomes of Crohn’s perianal fistulas treatment: anti-TNF with surgical closure versus anti-TNF alone (PISA-II) - A patient preference RCTECCO'22
Year: 2022
Authors: Meima - van PraagMD, E.(1);Stoker, J.(2);D'Haens, G.(3);Gecse, K.(4);Dijkgraaf, M.(5);Bemelman, W.(1);Buskens, C.(1);
(1)Amsterdam UMC, Surgery, Amsterdam, The Netherlands;(2)Amsterdam UMC, Radiology and Nuclear Medicine, Amsterdam, The Netherlands;(3)Amsterdam UMC, Gastroenterology and Hepatology, Gastroenterology and Hepatology, The Netherlands;(4)Amsterdam UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(5)Amsterdam UMC, Clinical Epidemiology- Biostatistics and Bioinformatics, Amsterdam, The Netherlands;
DOP31: Efficacy and safety of bone marrow-derived mesenchymal stem cells in refractory perianal fistulae in Crohn’s Disease: Results from a prospective monocentric studyECCO'22
Year: 2022
Authors: Reenaers Dr, C.(1);Vieujean , S.(1);Coimbra , C.(2);Gillard , R.(3);Meunier , P.(3);Boutaffala , L.(1);Louis , E.(1);
(1)CHU Liège- Sart Tilman, Department of Gastroenterology, Liège, Belgium;(2)CHU Liège- Sart Tilman, Department of abdominal surgery, Liège, Belgium;(3)CHU Liège- Sart Tilman, Department of radiology, Liège, Belgium;
DOP32: Biologic treatment does not reduce the risk of postoperative peristomal pyoderma gangrenosum in Crohn’s Disease patientsECCO'22
Year: 2022
Authors: Iesalnieks, I.(1);
(1)Evangelisches Krankenhaus Kalk, Department of surgery, Cologne, Germany;
DOP33: Role of adherent and invasive E. coli in Crohn’s Disease: Lessons from the postoperative recurrence modelECCO'22
Year: 2022
Authors: Buisson, A.(1);Sokol, H.(2);Hammoudi, N.(3);Nancey, S.(4);Treton, X.(5);Nachury, M.(6);Fumery, M.(7);Hébuterne, X.(8);Rodrigues, M.(9);Hugot, J.P.(10);Boschetti, G.(4);Stefanescu, C.(5);Wils , P.(6);Seksik, P.(2);Le Bourhis, L.(3);Bezault, M.(11);Sauvanet, P.(9);Pereira, B.(12);Allez, M.(3);Barnich, N.(9);
(1)University Hospital Estaing, Department of Gastroenterology- IBD Unit, Clermont-Ferrand, France;(2)AP-HP Saint-Antoine Hospital, IBD Unit, Paris, France;(3)AP-HP Saint-Louis Hospital, IBD Unit, Paris, France;(4)HCL-Lyon Sud, IBD Unit, Lyon, France;(5)AP-HP Beaujon Hospital, IBD Unit, Paris, France;(6)CHRU Lille, IBD Unit, Lille, France;(7)CHU Amiens, IBD Unit, Amiens, France;(8)CHU Nice, IBD Unit, Nice, France;(9)Université Clermont Auvergne, M2iSH, Clermont--Ferrand, France;(10)Centre de recherche sur l’inflammation- INSERM UMR 1149- Assistance Publique-Hôpitaux de Paris- Université de Paris, IBD Unit, Paris, France;(11)REMIND group, Administrative staff, Paris, France;(12)University Hospital Estaing, DRCI- Statistics Unit, Clermont-Ferrand, France;REMIND study group
DOP34: Comparison of the risk of clinical recurrence after ileocolonic resection for Crohn's Disease for modified Rutgeerts' score i2a and i2b categories: Individual patient data meta-analysisECCO'22
Year: 2022
Authors: Riviere, P.(1);Pekow, J.(2);Hammoudi, N.(3);Wils, P.(4);De Cruz, P.(5);Wang, C.(6);Mañosa, M.(7);Ollech, J.(2);Allez, M.(3);Nachury, M.(4);Kamm, M.(5);Maya, A.(2);Ferrante, M.(8);Buisson, A.(9);Singh, S.(10);Laharie, D.(1);Momar, D.(11);Fumery, M.(12);
(1)Bordeaux University Hospital, Gastroenterology unit, Pessac, France;(2)University of Chicago, Gastroenterology, Chicago, United States;(3)Hôpital Saint-Louis, Gastroenterology, Paris, France;(4)Lille University Hospital, Gastroenterology, Lille, France;(5)The Austin Hospital, Gastroenterology, Melbourne, Australia;(6)Mount Sinai Hospital, Gastroenterology, New York, United States;(7)Hospital Germans Trias, Gastroenterology, Badalona, Spain;(8)Leuven University Hospitals, Gastroenterology, Leuven, Belgium;(9)Clermont Ferrand University Hospitals, Gastroenterology, Clermont Ferrand, France;(10)UC San Diego Health, Gastroenterology, San Diego, United States;(11)Amiens University Hospitals, Statistics, Amiens, France;(12)Amiens University Hospitals, Gastroenterology, Amiens, France;
DOP35: Increasing incidence of pouchitis among patients undergoing ileal pouch-anal anastomosis between 1996 and 2018: A population-based Danish cohort studyECCO'22
Year: 2022
Authors: Barnes, E.(1);Allin, K.(2);Iversen, A.(2);Herfarth, H.(1);Jess, T.(2);
(1)University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, Chapel Hill, United States;(2)Center for Molecular Prediction of Inflammatory Bowel Disease- Aalborg University, Department of Clinical Medicine, Copenhagen, Denmark;
DOP36: Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter studyECCO'22
Year: 2022
Authors: Sallette, M.(1);Bouhnik, Y.(2);Nachury, M.(3);Bellanger, C.(4);Laharie, D.(5);Amiot, A.(6);Peyrin-Biroulet, L.(7);Roblin, X.(8);Altwegg, R.(9);Buisson, A.(10);Reenaers, C.(11);Bouguen, G.(12);Vuitton, L.(13);Bourreille, A.(14);Gilletta, C.(15);Serrero, M.(16);Hébuterne, X.(17);Filippi, J.(18); Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)
(1)Archet 2 University Hospital, Gastroenterology, Nice, France;(2)Beaujon University Hospital, Gastroenterology, Paris, France;(3)Lille University Hospital, Gastroenterology, Lille, France;(4)Kremlin Bicêtre Hospital, Gastroenterology, Paris, France;(5)Haut Lévêque Hospital, Gastroenterology, Bordeaux, France;(6)Henri Mondor University Hospital, Gastroenterology, Paris, France;(7)Nancy University Hospital, Gastroenterology, Nancy, France;(8)Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France;(9)Montpellier University Hospital, Gastroenterology, Montpellier, France;(10)Clermont-Ferrand University Hospital, Gastroenteroogy, Clermont-Ferrand, France;(11)Liège University Hospital, Gastroenterology, Liège, Belgium;(12)Rennes University Hospital, Gastroenterology, Rennes, France;(13)Besançon University Hospital, Gastroenterology, Besançon, France;(14)Nantes University Hospital, Gastroenteroogy, Nantes, France;(15)Toulouse University Hospital, Gastroenterology, Toulouse, France;(16)Nord University Hospital, Gastroenterology, Marseille, France;(17)Archet 2 University Hospital, Gastroenterology, Nice, France;(18)Archet 2 Unversity Hospital, Gastroenterology, Nice, France;
DOP37: Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studiesECCO'22
Year: 2022
Authors: SCHREIBER, S.(1);Loftus Jr, E.V.(2);Maaser, C.(3);Danese, S.(4,5);Rudolph, C.(6);Jongen, R.(6);De Haas, A.(6);Oortwijn, A.(6);Vermeire, S.(7);
(1)Kiel University, Medicine I, Kiel, Germany;(2)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;(3)Hospital Lüneburg, Outpatients Department of Gastroenterology, Lüneburg, Germany;(4)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(5)Vita-Salute, San Raffaele University, Milan, Italy;(6)Galapagos, Nv, Leiden, The Netherlands;(7)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
DOP38: Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1ECCO'22
Year: 2022
Authors: Vermeire, S.(1);Colombel, J.F.(2);Takeuchi, K.(3);Gao, X.(4);Panaccione, R.(5);Danese, S.(6);Dubinsky, M.(7);Schreiber, S.(8);Ilo, D.(9);Finney-Hayward, T.(9);Zhou, W.(9);Phillips, C.(9);Yao, X.(9);Zhou, Q.(9);Loftus, E.(10);
(1)University Hospital Leuven, none, Leuven, Belgium;(2)Icahn School of Medicine at Mount Sinai, none, New York City, United States;(3)Tsujinaka Hospital Kashiwanoha- Kashiwa, Division of Gastroenterology and Hepatology, Chiba, Japan;(4)The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(5)University of Calgary, Division of Gastroenterology and Hepatology, Alberta, Canada;(6)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Department of Gastroenterology and Endoscopy, Milan, Italy;(7)Icahn School of Medicine at Mt Sinai, Department of Pediatric Gastroenterology, New York, United States;(8)University Hospital Schleswig-Holstein, none, Kiel, Germany;(9)AbbVie- Inc, none, North Chicago, United States;(10)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;
DOP39: Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programmeECCO'22
Year: 2022
Authors: Higgins, P.(1);Colombel, J.F.(2);Reguiero, M.(3);Parkes, G.(4);Ilo, D.(5);Philips, C.(5);Yao, X.(6);Cheng, E.(6);Schreiber, S.(7);
(1)University of Michigan, Department of Internal Medicine, Ann Arbor, United States;(2)Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States;(3)Cleveland Clinic Foundation, Department of Gastroenterology and Hepatology, Cleveland, United States;(4)Royal London Hospital, Department of Gastroenterology, London, United Kingdom;(5)AbbVie Inc, Research and Development, North Chicago- Illinois, United States;(6)AbbVie Inc, Data & Statistical Sciences, North Chicago- Illinois, United States;(7)University Hospital Schleswig-Holstein, Department of Internal Medicine, Kiel, Germany;
DOP40: Impact of corticosteroid usage on efficacy and safety outcomes in patients receiving upadacitinib for Ulcerative ColitisECCO'22
Year: 2022
Authors: Raine, T.(1);Ishiguro, Y.(2);Rubin, D.(3);Finney-Hayward, T.(4);Dapo, I.(5);Phillips, C.(5);Cheng, E.(6);Targownik, L.(7);Loftus- Jr., E.V.(8);
(1)Addenbrooke's Hospital- Cambridge University Hospitals, Department of Gastroenterology, Cambridge, United Kingdom;(2)Hirosaki General Medical Centre- National Hospital Organisation, Department of Clinical Research, Hirosaki, Japan;(3)The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(4)AbbVie Ltd., Gastroenterology, Maidenhead, United Kingdom;(5)AbbVie Ltd., Research and Development, North Chicago, United States;(6)AbbVie Ltd., Data & Statistical Science, North Chicago, United States;(7)Mount Sinai Hospital- University of Toronto, Division of Gastroenterology and Hepatology, Toronto, Canada;(8)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;